Biotech: Page 2


  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

    Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

    By June 13, 2024
  • digital blue pill on computer chip background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Behind the powerful computations, AI’s role in pharma is still beset by challenges

    Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.

    By June 12, 2024
  • cancer healthcare Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • MDMA
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Despite adcomm rejection, Lykos CEO sees future for MDMA drug

    Although the rebuff makes approval “a bit more challenging,” Lykos is moving forward with the psychedelic-based treatment for PTSD.

    By Alexandra Pecci • June 12, 2024
  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA’s platform designation aims to ease R&D pain points

    A new program creates approval pathways for multiple drugs developed on the same platform. 

    By June 11, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Behind Big Pharma’s layoffs — is there an end in sight?

    A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

    By Kelly Bilodeau • June 10, 2024
  • gambling chips
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s R&D gamble: picking pipeline winners in a risky field

    How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

    By June 7, 2024
  • City of Hope Helford Clinical Research Hospital in Duarte, California
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

    Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.

    By June 6, 2024
  • FibroBiologics CEO Pete O'Heeron at the opening bell for the Nasdaq
    Image attribution tooltip
    Permission granted by FibroBiologics
    Image attribution tooltip
    Biotech Spotlight

    Regenerative cell therapy biotech uses IPO to blast into human trials

    Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

    By June 5, 2024
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

    Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

    By June 3, 2024
  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

    By June 3, 2024
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    After two Big Pharma deals, Nimbus looks to keep the hits coming

    With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.

    By Kelly Bilodeau • June 3, 2024
  • Symbolic of Sino-American relations, the flag of the United States of America and the flag of the Republic of China fly together on flag poles next to each other on a sunny, windy day.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Deadline looms for Chinese biotech contracts

    The latest version of The Biosecure Act working its way through Congress could make waves in the U.S. biotech industry.

    By May 31, 2024
  • 3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

    By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

    By Alexandra Pecci • May 30, 2024
  • Robot arm DNA
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can robots break the cell therapy bottleneck?

    A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

    By May 29, 2024
  • two syringes
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where competition is heating up in pharma

    The stage is set for potential blockbuster-level showdowns targeting these three indications.

    By May 24, 2024
  • Pascal Soriot, CEO, AstraZeneca
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

    Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

    By May 23, 2024
  • Pittsburg
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 up-and-coming US biotech hotspots

    These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.

    By Alexandra Pecci • May 21, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies

    Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said. 

    By May 20, 2024
  • Google logo reflection in an eye
    Image attribution tooltip
    Leon Neal / Getty Images via Getty Images
    Image attribution tooltip

    Why AlphaFold 3 is stirring up so much buzz in pharma

    The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.

    By Kelly Bilodeau • May 20, 2024
  • Businessman choosing his business direction.
    Image attribution tooltip

    shutterstock.com/Sergey Nivens

    Image attribution tooltip
    Sponsored by BioLineRx

    Flipping a biotech incubator into a commercial company

    How persistence led to BioLineRx’s first approved therapy and promising pipeline.

    May 20, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Investors put $400M into biotech licensing obesity drugs from China

    The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

    By Gwendolyn Wu • May 16, 2024
  • An auto-injector of Eli Lilly's metabolic drug Mounjaro is seen on a gray background
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip

    Big Pharma’s most improved drugs: a new generation of blockbusters

    The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.

    By May 14, 2024
  • A sign shows the logo of Eli Lilly's Research Laboratories
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown

    The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.

    By May 9, 2024
  • regenerative medicine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Using the body as ‘a bioreactor’ — a regenerative medicine expert on where the field is headed

    The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.”

    By Alexandra Pecci • May 7, 2024
  • novavax shot
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip

    Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma

    With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance.

    By May 3, 2024